Literature DB >> 17926098

Robot-assisted thoracolaparoscopic esophagolymphadenectomy for esophageal cancer.

J Boone, I H M Borel Rinkes, R van Hillegersberg.   

Abstract

Entities:  

Mesh:

Year:  2007        PMID: 17926098      PMCID: PMC2077355          DOI: 10.1007/s00464-007-9604-2

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


× No keyword cloud information.
With interest we read the article by Kernstine and colleagues, describing their initial experience with totally robot-assisted thoracolaparoscopic esophagolymphadenectomy [1]. Their series consisted of three consecutive groups, each combining the robot-assisted thoracoscopic procedure with either open abdominal surgery, laparoscopy, or robot-assisted laparoscopy. These groups represent the learning curve followed by the authors. Indeed, we followed a similar strategy with our first 21 cases of robot-assisted thoracolaparoscopic esophagolymph-adenectomy, published in this journal in 2006 [2]. We experienced a steep learning curve and found a reduction of the pulmonary complication rate only after we had introduced the laparoscopic abdominal phase. This is consistent with previous reports of conventional thoracolaparoscopic esophagectomy [3]. Before introducing the procedure in our clinic, we tested the port position and the position of the robotic system extensively in a cadaveric study and came to a thoracic position similar to that presented by Kernstine et al. [1]. The position of the robotic system in our setup, however, is more dorsocranial [2, 4]. In our experience, the Da Vinci robotic system (Intuitive Surgical, Inc, Sunnyvale, CA, USA) has been very beneficial during the thoracoscopic phase of esophageal resection and lymph node dissection, allowing for a very precise dissection along the vital mediastinal structures. Yet, we have found the robotic system less suitable for the abdominal phase, requiring maneuvers with large amplitude leading to collisions of the robotic arms. Especially during the dissection along the greater curvature of the stomach, a large area of various positions must be covered. We therefore perform the abdominal phase by conventional laparoscopy using an ultrasonic dissector device. Selective use of the robot can save operating time. The median operating time for robot-assisted thoracoscopy with conventional laparoscopy is 7.5 h [2], compared with 11.2 h in case of the totally robotic procedure [1]. The authors do not describe any benefit from use of the robotic system during the abdominal phase. The median number of lymph nodes dissected in the current series was less than in our series (18 [1] vs 20 [2]), eventhough the authors denominate their procedure a three-field lymph node dissection. A formal cervical lymph node dissection was not performed in this series, so actually a two-field lymphadenectomy was performed [5]. With regard to the azygos vein, we agree with the authors that the trunk of this vein can be preserved during robot-assisted thoracoscopic esophagolymphadenectomy. We have recently shown in a cadaveric study that preservation of the azygos vein during thoracic esophagolymphadenectomy did not substantially affect the extent of mediastinal lymph node harvesting [6].
  5 in total

1.  The effect of azygos vein preservation on mediastinal lymph node harvesting in thoracic esophagolymphadenectomy.

Authors:  J Boone; M E I Schipper; R L A W Bleys; I H M Borel Rinkes; R van Hillegersberg
Journal:  Dis Esophagus       Date:  2008       Impact factor: 3.429

2.  First experience with robot-assisted thoracoscopic esophagolymphadenectomy for esophageal cancer.

Authors:  R van Hillegersberg; J Boone; W A Draaisma; I A M J Broeders; M J M M Giezeman; I H M Borel Rinkes
Journal:  Surg Endosc       Date:  2006-05-15       Impact factor: 4.584

3.  Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma.

Authors:  T Lerut; P Nafteux; J Moons; W Coosemans; G Decker; P De Leyn; D Van Raemdonck; N Ectors
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

4.  The first series of completely robotic esophagectomies with three-field lymphadenectomy: initial experience.

Authors:  K H Kernstine; D T DeArmond; D M Shamoun; J H Campos
Journal:  Surg Endosc       Date:  2007-06-26       Impact factor: 4.584

5.  Minimally invasive esophagectomy: outcomes in 222 patients.

Authors:  James D Luketich; Miguel Alvelo-Rivera; Percival O Buenaventura; Neil A Christie; James S McCaughan; Virginia R Litle; Philip R Schauer; John M Close; Hiran C Fernando
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

  5 in total
  5 in total

Review 1.  Total minimally invasive esophagectomy for esophageal cancer: approaches and outcomes.

Authors:  Danica N Giugliano; Adam C Berger; Ernest L Rosato; Francesco Palazzo
Journal:  Langenbecks Arch Surg       Date:  2016-07-11       Impact factor: 3.445

Review 2.  [Minimally invasive and robotic-assisted surgical management of upper gastrointestinal cancer].

Authors:  P P Grimminger; H F Fuchs
Journal:  Chirurg       Date:  2017-12       Impact factor: 0.955

3.  Three-dimensional vs two-dimensional video assisted thoracoscopic esophagectomy for patients with esophageal cancer.

Authors:  Zhao Li; Jing-Pei Li; Xiong Qin; Bin-Bin Xu; Yu-Dong Han; Si-Da Liu; Wen-Zhuo Zhu; Ming-Zheng Peng; Qiang Lin
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

4.  Modified exposure method for gastric mobilization in robot-assisted esophagectomy.

Authors:  Yu Zheng; Xi-Wen Zhao; Han-Lu Zhang; Zi-Hao Wang; Yun Wang
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

5.  Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis.

Authors:  Yongxing Gong; Steven E Schumacher; Wei H Wu; Fanying Tang; Rameen Beroukhim; Timothy A Chan
Journal:  Neoplasia       Date:  2016-12-27       Impact factor: 5.715

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.